Clinical study on disease monitoring and therapeutic guidance roles of the BP180NC16A-ELISA index in patients with bullous pemphigoid
10.3760/cma.j.issn.1008-1372.2013.08.003
- VernacularTitle:BP180NC16a-ELISA指数对大疱性类天疱疮病情监测与治疗指导的临床研究
- Author:
Ying ZHAO
;
Xiguang LIU
;
Ying SONG
;
Yanhui JIA
- Publication Type:Journal Article
- Keywords:
Pemphigoid,bullous/therapy;
Pemphigoid,bullous/epidemiology;
Enzyme-linked immunosorbent assay
- From:
Journal of Chinese Physician
2013;15(8):1018-1021
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the use of enzyme-linked immunosorbent assay(ELISA) to test the serological BP180NC16A-ELISA index in patients with bullous pemphigoid (BP) and investigate the relationship of this index with disease monitoring and therapeutic guidance.Methods The serological BP180NC16a-ELISA index at different times was examined in twenty BP patients with ELISA kit and monitor changes of pre-treatment BP180NC16a-ELISA index condition score and efficacy relationship..Results Twenty patients tested by ELISA had 19 cases of positive patients with positive rate of 95.0% and one case negative with negative rate of 5.0%.After treatment,19 cases (19.60 ±4.63)d became stable,and condition score was (3.75 ± 1.37) points.After continued treatment (28.75 ± 6.11) d entering clinical remission,condition score was (2.25 ± 1.21)points.Compared with the score before treatment condition [(5.55 ± 1.61) points],differences were statistically significant (Z =-3.808,-3.965,P < 0.01),and clinical remission score below clinically stable condition (Z =-3.808,P <0.01).A total of 19 cases of patients' pre-ELISA treatment index were positive correlation with after treatment stable period and clinical remission period (rs =0.788,0.752,P < 0.01).Conclusions This study demonstrated that ELISA-detected BP180NCI6a-ELISA index was positively correlated with the BP disease severity and clinical course,which could be as the guideline to monitor and clinical treatment.